ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Sonoma Pharmaceuticals, Inc. ?
1
Poor long term growth as Net Sales has grown by an annual rate of -3.39% over the last 5 years
2
With a growth in Net Profit of 53.37%, the company declared Very Positive results in Dec 25
- The company has declared positive results for the last 3 consecutive quarters
- NET SALES(HY) At USD 9.95 MM has Grown at 39.34%
- NET PROFIT(HY) Higher at USD -1.35 MM
- RAW MATERIAL COST(Y) Fallen by -6.67% (YoY)
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -25.23%, its profits have risen by 10.1%
4
Increasing Participation by Institutional Investors
- Institutional investors have increased their stake by 1.49% over the previous quarter and collectively hold 9.36% of the company
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors
5
Underperformed the market in the last 1 year
- Even though the market (S&P 500) has generated returns of 14.90% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -25.23% returns
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Sonoma Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Sonoma Pharmaceuticals, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Sonoma Pharmaceuticals, Inc.
-21.54%
-0.35
120.62%
S&P 500
14.9%
0.77
19.29%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-3.39%
EBIT Growth (5y)
3.42%
EBIT to Interest (avg)
-4.46
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.16
Sales to Capital Employed (avg)
2.91
Tax Ratio
18.92%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
9.36%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.22
EV to EBIT
-0.63
EV to EBITDA
-0.67
EV to Capital Employed
1.73
EV to Sales
0.10
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-271.98%
ROE (Latest)
-98.19%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend10What is working for the Company
NET SALES(HY)
At USD 9.95 MM has Grown at 39.34%
NET PROFIT(HY)
Higher at USD -1.35 MM
RAW MATERIAL COST(Y)
Fallen by -6.67% (YoY
INVENTORY TURNOVER RATIO(HY)
Highest at 3.2 times
DEBTORS TURNOVER RATIO(HY)
Highest at 7.4 times
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Sonoma Pharmaceuticals, Inc.
Net Sales
At USD 9.95 MM has Grown at 39.34%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Net Profit
Higher at USD -1.35 MM
than preceding 12 month period ended Dec 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Inventory Turnover Ratio
Highest at 3.2 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Debtors Turnover Ratio
Highest at 7.4 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -6.67% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
